AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 JUL 1 - (NewsRx.com & NewsRx.net) -- Recombinant human insulin-like growth factor-1 gene therapy has the potential to improve recovery of pudendal nerve structure and function, a study in rats suggests.
"Injured nerves and their motor units may undergo enhanced recovery when exposed to recombinant human insulin-like growth factor-1 (rhIGF-1)," said scientists writing in the International Urogynecology Journal.
In their study, "[t]he external anal sphincter muscle in the female rat was denervated to model incontinence. The treatment-group muscle was injected with rhIGF-1 plasmid, whereas in the control group the plasmid lacked the cDNA insert and the normal group received neither surgery nor treatment."
J.M. Kerns and colleagues at Rush Presbyterian-St. Luke's Medical Center reported that "[e]lectromyography data at 56 days post-surgery indicated more re-innervation without fibrillation potentials in the treatment group (2 of 6) than in the control group (0 of 6).
"The histology of the regenerated axons in the pudendal nerve distal to the crush site also suggested an improved recovery in the treatment group. The number of motor neurons retrogradely labeled with horseradish ...
Source: HighBeam Research, Recombinant IGF-1 gene therapy may improve nerve structure, function...